GlassScriptPhysician profile
Shahnaz Malekan
NPI 1568608271
$3,367.23
in general payments reported to CMS, 2019-2025
17 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $125 · 2021: $261 · 2022: $418 · 2023: $1,033 · 2024: $618 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $446.10 | 2022-2024 | |
| Allergan, INC. | $376.41 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $374.70 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $293.90 | 2022-2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $260.02 | 2023 | Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.31 | 2022-2025 | Caplyta |
| Corcept Therapeutics | $202.57 | 2025 | Korlym |
| Abbott Laboratories | $150.00 | 2024 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $136.47 | 2021 | |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Amgen INC. | $125.00 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $124.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.94 | 2023 | Cycloset |
| Intuity Medical INC | $111.11 | 2022 | |
| Neuronetics, INC. | $107.84 | 2024 | Neurostar Tms Therapy System |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $104.16 | 2019 | |
| Alkermes, INC. | $98.71 | 2025 | Aristada, Aristada Initio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahnaz Malekan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.